Social Capital Suvretta Holdings Corp. III (DNAC): Price and Financial Metrics

Social Capital Suvretta Holdings Corp. III (DNAC): $9.28

0.72 (-7.20%)

POWR Rating

Component Grades








DNAC Price/Volume Stats

Current price $9.28 52-week high $10.55
Prev. close $10.00 52-week low $8.03
Day low $9.24 Volume 338,800
Day high $10.55 Avg. volume 178,857
50-day MA $9.83 Dividend yield N/A
200-day MA $9.86 Market Cap 237.94M

DNAC Stock Price Chart Interactive Chart >

Social Capital Suvretta Holdings Corp. III (DNAC) Company Bio

Social Capital Suvretta Holdings Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. The company was incorporated in 2021 and is based in Henderson, Nevada.

DNAC Latest News Stream

Event/Time News Detail
Loading, please wait...

DNAC Latest Social Stream

Loading social stream, please wait...

View Full DNAC Social Stream

Latest DNAC News From Around the Web

Below are the latest news stories about SOCIAL CAPITAL SUVRETTA HOLDINGS CORP III that investors may wish to consider to help them evaluate DNAC as an investment opportunity.

DNAC Stock: 11 Things to Know Ahead of the ProKidney SPAC Merger

Palihapitiya's SPAC with ProKidney is expected to close during Q3 of this year.

Eddie Pan on InvestorPlace | March 1, 2022

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease

Article published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), today announced the publication of the trial design of its Phase II clinical study of its novel Renal Autologous Cell Therapy (REACT®) in the American Journal of Nephrology. The paper, titled Novel Renal Autologous Cell

Yahoo | January 27, 2022

7 Worst SPACs for Smart Investors to Skip in 2022

SPACs may make a comeback in 2022.

Ian Bezek on InvestorPlace | January 26, 2022

DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger

Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney.

Joel Baglole on InvestorPlace | January 18, 2022

SOFI Stock: 11 Reasons Why Investors Are Banking On a SoFi Bank Charter

SoFi Technologies (SOFI) stock is on the move Tuesday as investors discuss a bank charter for the company and what it could do to the stock.

William White on InvestorPlace | January 18, 2022

Read More 'DNAC' Stories Here

DNAC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2023 N/A
2022 0.00%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!